信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

交易中 08-25 12:16:39 EDT

4.97

+0.00

0.00%

最高5.00	最低4.95	成交量3.84万
今开4.97	昨收4.97	日振幅1.11%
总市值2.41亿	流通市值1.77亿	总股本4,841万
成交额19.10万	换手率0.11%	流通股本3,555万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.97,"timestamp":1787674594166,"preClose":4.97,"halted":0,"volume":38352,"delay":0,"changeRate":0,"floatShares":35552300,"shares":48413462,"eps":0.239856,"marketStatus":"交易中","change":0,"latestTime":"08-25 12:16:39 EDT","open":4.97,"high":5,"low":4.945,"amount":190999.1231664,"amplitude":0.011066,"askPrice":4.97,"askSize":256,"bidPrice":4.96,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.239856,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.97,"dividendRate":0.036217,"preHourTrading":{"tag":"盘前","latestPrice":4.796,"preClose":4.97,"latestTime":"08:14 EDT","volume":100,"amount":479.6,"timestamp":1787660091970,"change":-0.174,"changeRate":-0.03501,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.97,"preClose":4.97,"latestTime":"19:30 EDT","volume":2643,"amount":13135.71,"timestamp":1787614204064,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.530371,"impliedVol":0.754,"impliedVolPercentile":0.3586},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2662755435","title":"一架美国空军波音C‑17“环球霸王III”运输机已从伏努科沃机场起飞。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662755435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662755435?lang=zh_cn&edition=full","pubTime":"2026-08-25 23:41","pubTimestamp":1787672479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2326559502.SGD","MISL","PPA","BK4187","BK4551","BK4134","IE000M9KFDE8.USD","IDEF","LU0162691827.USD","LU1429558221.USD","ITA","BOEG","BOED","FOWF","III","NATO","BK4516","BOEU","BA","BK4564","BK4585","BK4588","LU1435385759.SGD","JETU","BILT","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660233473","title":"打一针即可追杀癌细胞！全球首款癌症疫苗III期临床成功，离普通患者有多远","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233473","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660233473?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:54","pubTimestamp":1787237674,"startTime":"0","endTime":"0","summary":"一针疫苗能治癌？8月19日，默沙东与莫德纳联合宣布，个性化mRNA癌症疫苗IntismeranAutogene（研发代号mRNA-4157/V940）联合PD-1抑制剂帕博利珠单抗（俗称“K药”）治疗黑色素瘤的Ⅲ期临床试验取得积极结果，无复发生存期和无远处转移生存期均达到关键终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203848194326.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203848194326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4134","159646","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828518","title":"康希诺生物：破伤风疫苗获国家药监局NDA批准，III期临床免疫原性优于对照疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828518","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660828518?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:43","pubTimestamp":1787222614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660364424","title":"美股异动 |  和黄医药(HCM.US)涨近4% SAFFRON III期研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660364424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660364424?lang=zh_cn&edition=full","pubTime":"2026-08-17 23:39","pubTimestamp":1786981164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HCM","BK4588","BK4531","III","BK4007","BK4134","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248062","title":"阿斯利康(AZN.US)/第一三共ADC一线治疗肺癌III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660248062?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:44","pubTimestamp":1786970699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康和第一三共联合宣布Enhertu单药一线治疗非小细胞肺癌的III期DESTINY-Lung04研究取得了高水平的积极结果。结果显示，Enhertu组患者的PFS较标准治疗组实现了统计学显著且临床意义显著的改善。值得一提的是，Enhertu是第一个在III期研究中成功证明单药相较标准治疗作为一线治疗方案能够改善NSCLC患者的PFS的ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","LU1829250122.USD","LU2237443978.SGD","LU0128525929.USD","LU0109394709.USD","III","LU2237443549.SGD","ADC","LU0889565916.HKD","LU2236285917.USD","NETL","BK4134","IE00B3T34201.USD","LU2237443622.USD","LU0432979614.USD","LU0708994859.HKD","BK4231","LU0029864427.USD","BK4080","BK4007","AZNH","LU0289739699.SGD","LU0320765992.SGD","AZN","LU2237443465.HKD","LU2468319806.SGD","LU2417539215.USD","BK4585","LU2456880835.USD","LU2089984988.USD","LU0310800379.SGD","LU1267930573.SGD","BK4568","LU2237443382.USD","LU2237443895.HKD","BK4588","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股异动 | Argenx(ARGX.US)盘前涨超10% 自身免疫性肌炎药物Vyvgart III期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660481020?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4505","BK4585","IE00B4R5TH58.HKD","LU1983260115.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0889565916.HKD","IE0034235188.USD","BK4588","LU0823416689.USD","IE0002141913.USD","BK4139","ARGX","IE00BFTCPJ56.SGD","TBXU","BK4134","IE0009355771.USD","IBB","LU0320765992.SGD","LU2324357040.USD","IE00BJT1NW94.SGD","FMED","IE00B2B36J28.USD","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股异动丨Argenx SE盘前大涨超7%，Efgartigimod治疗肌炎III期试验成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660848605?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["TBXU","LU0889565916.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","IBB","BK4588","LU0320765992.SGD","IE0002141913.USD","ARGX","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4505","LU1983260115.SGD","LU0823416689.USD","III","IE0034235188.USD","BK4585","FMED","BK4134","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0009355771.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810460","title":"和黄医药宣布沃瑞沙®和泰瑞沙®的联合疗法在SAFFRON全球III期研究中显示出具有统计学和临床意义的PFS和OS改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810460","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660810460?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:12","pubTimestamp":1786936320,"startTime":"0","endTime":"0","summary":"继SACHI III期研究支持了该疗法在中国获批后，SAFFRON全球研究的结果进一步印证了其坚实的疗效，并将为泰瑞沙和沃瑞沙联合疗法的全球注册提供明确的数据支持。\" 沃瑞沙和泰瑞沙联合疗法的安全性特征与已知的各药物的安全性保持一致，且没有发现新的安全性问题。基于SACHI III期研究，沃瑞沙和泰瑞沙联合疗法已于中国获批用于治疗接受EGFR TKI治疗后疾病进展的伴有MET扩增的EGFR突变的局部晚期或转移性非小细胞肺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["PFS","BK1587","III","BK1588","HCM","BK4134","BK1191","00013","BK4585","BK4007","BK4211","BK4531","BK4195","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660170641","title":"国泰海通｜计算机：上海发布软件和信息服务业“十五五”规划，DeepSeek与GLM持续推动模型能力升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170641","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660170641?lang=zh_cn&edition=full","pubTime":"2026-08-16 22:18","pubTimestamp":1786889880,"startTime":"0","endTime":"0","summary":"报告导读：上周，上海发布软件和信息服务业“十五五”规划，提出实施“百千万”智算集群工程；DeepSeek V4 Pro正式版上线；智谱发布GLM-5.3。8月11日，上海市经信委印发《上海市软件和信息服务业发展“十五五”规划》，提出到2030年产业规模力争达到4万亿元、产业增加值突破1.1万亿元。DeepSeek V4 Pro正式版上线，Agent能力升级并进一步完善开发者生态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning","research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650540470&idx=4&sn=a4717a507aec128f5b283e38e6c09cc8&chksm=892427d2e948e645d6aae9c0901cf5a017bbe85cfab8c6d05a2bf17bdb89c717b9b83857157a&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["02611","159998","159180","601211","III","VGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658266669","title":"一图读懂｜上海市软件和信息服务业发展“十五五”规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2658266669","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658266669?lang=zh_cn&edition=full","pubTime":"2026-08-12 12:23","pubTimestamp":1786508580,"startTime":"0","endTime":"0","summary":"来源：上海经信委","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/2026-08-12/doc-inimzumt4014959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VGT","159180","BK4585","III","BK4588","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658913497","title":"AGILE DEFENSE：获得价值8800万美元的美国海军陆战队网络空间作战大队高级网络支持服务III重新竞标合同。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658913497","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658913497?lang=zh_cn&edition=full","pubTime":"2026-08-11 21:12","pubTimestamp":1786453970,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995998","title":"上海：到2030年把软件和信息服务业打造成经济增长“动力源” 产业规模力争达到4万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995998","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658995998?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:00","pubTimestamp":1786438810,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["VGT","159180","BK4585","BK0156","BK0077","600405","III","BK0214","BK4588","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995548","title":"上海印发《上海市软件和信息服务业发展“十五五”规划》。到2030年，把上海软件和信息服务业打造成经济增长“动力源”，AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658995548?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:57","pubTimestamp":1786438665,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["QTOC","BK4134","CHAT","ARTY","AGIX","VTHR","VGT","BK4585","III","AIPO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658511964","title":"印度央行：各银行按计划顺利落实巴塞尔协议III准则。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658511964","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658511964?lang=zh_cn&edition=full","pubTime":"2026-08-11 13:29","pubTimestamp":1786426170,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4523","INCO","PBEU","SMIN","PIN","GSIB","SCIN","EPI","TAJX","FLIBF","BK4134","INDA","INDL","IND","INQQ","NDIA","NFTY","161121","INDE","INDY","IOPP","GIND","IMVP","III","BK4585","BK4588","QTPI","FLIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658360602","title":"劲方医药：GFH375治疗肺癌III期临床正式启动 首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2658360602","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658360602?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:13","pubTimestamp":1786324380,"startTime":"0","endTime":"0","summary":"8月10日，劲方医药（02595）发布公告，口服KRASG12D抑制剂GFH375针对非小细胞肺癌的注册性III期“麒麟飞01”研究正式启动，全国超40家中心参与，南京鼓楼医院完成首例患者入组。该药物此前已启动胰腺癌III期“麒麟翼01”研究，并拿下NSCLC、胰腺癌两项国内突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608103836075023.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608103836075023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","09939","159938","BK4134","III","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658560637","title":"康诺亚-B：CM512 II期临床试验达到所有研究终点，将启动III期研究并明确300mg半年给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2658560637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658560637?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:57","pubTimestamp":1786323475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["III","PSYK","MDTX","IBBQ","IBBJ","BK4134","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657681894","title":"百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2657681894","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657681894?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:22","pubTimestamp":1786008136,"startTime":"0","endTime":"0","summary":"【百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药】百利天恒公告，公司自主研发的创新生物药BL-M14D1联合PD-L1单抗对比含铂化疗联合PD-L1单抗治疗一线广泛期小细胞肺癌的全球多中心III期临床试验已于近日完成首例受试者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063833940921.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063833940921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","688506","BK1161","IBBQ","91194","159992","MDTX","BMED","MEDX","III","PSYK","06978","IBBJ","BK4134","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657895786","title":"百利天恒：注射用BL-M14D1联合免疫治疗一线SCLC全球III期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2657895786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657895786?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:04","pubTimestamp":1786007078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1815336091.USD","BL","BK4023","III","LU0757428866.USD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570486","title":"困扰学术界近半个世纪，北京谱仪III实验首次认证胶球的存在","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570486","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657570486?lang=zh_cn&edition=full","pubTime":"2026-08-06 08:42","pubTimestamp":1785976921,"startTime":"0","endTime":"0","summary":"IT之家 8 月 6 日消息，据中国科学院高能物理研究所，北京时间 8 月 6 日，北京正负电子对撞机上的北京谱仪 III 实验 国际合作组在巴西举行的国际高能物理大会上，以特别大会报告的形式宣布：经过 15 年的持续研究，BESIII 实验建立了证明胶球存在的完整证据链，解开了困扰学术界近半个世纪的胶球存在之谜。然而，半个世纪以来，实验上一直未能找到胶球。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vMWaGKcYLX","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589606","title":"歌礼制药-B早盘涨逾5% GLP-1口服小分子ASC30启动全球III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589606","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656589606?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:55","pubTimestamp":1785812100,"startTime":"0","endTime":"0","summary":"8月3日，歌礼制药宣布，每日一次口服小分子GLP-1已获得美国食品药品监督管理局的III期临床研究批准。ASC30是歌礼口服小分子肥胖症治疗管线组合中的核心支柱。公司已针对ASC30长期体重管理适应症启动了一项全球III期临床项目，将在美国、欧洲和加拿大开展两项关键临床试验，将入组约4，600名肥胖或超重受试者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzv2245265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","GLP","JDOC","BK4590","BK1161","BK1515","BK4144","01672","BK1191","BK1574","01477","III"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":0.2876},{"period":"3month","weight":0.1452},{"period":"6month","weight":0.0597},{"period":"1year","weight":-0.0119},{"period":"ytd","weight":-0.1401}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.030463},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.00444},{"month":5,"riseRate":0.368421,"avgChangeRate":-0.021525},{"month":6,"riseRate":0.473684,"avgChangeRate":0.009959},{"month":7,"riseRate":0.473684,"avgChangeRate":0.014159},{"month":8,"riseRate":0.578947,"avgChangeRate":0.020177},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}